What this Trial Is About

Vitiligo is an autoimmune skin disorder causing white patches on the skin, affecting about 2% of people worldwide. It negatively impacts patients' quality of life and self-esteem. This research studies generalized vitiligo and focuses on evaluating a systemic treatment using a JAK inhibitor called baricitinib, combined with phototherapy, to understand their effects on disease progression and skin re-pigmentation. The study also measures serum s100B levels, a protein linked to melanocyte damage, to explore its relation to vitiligo and treatment response. Participants will receive oral baricitinib—4mg daily for adults and 2mg for children aged 10 to 16 years—or an oral mini pulse of dexamethasone, paired with narrowband ultraviolet B phototherapy twice weekly. The study spans from enrollment to three to six months post-treatment start, monitoring treatment effects on skin re-pigmentation and disease progression. Phototherapy sessions are conducted twice per week throughout the treatment period. During the study, participants will undergo blood tests to measure serum s100B at enrollment and after three months of treatment. Researchers will assess clinical outcomes including stopping vitiligo progression and achieving satisfactory re-pigmentation. Safety and treatment response will be monitored regularly through clinical evaluations. The total participation duration covers at least three months following treatment initiation, with ongoing assessments of skin condition and laboratory markers.

Vitiligo, New Treatment and Serum s100B